Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Drug Targeting Fat Synthesis In Cancer Cells Slows Tumor Growth

XTALKS VITALS NEWS

Cancer

Since Shaw’s team and other researchers have identified a link between fat metabolism and cancer, they sought out to determine whether fat synthesis blocking drugs could be useful anticancer agents.

Tweetables from this article:

Tweet: Compared to untreated animals with #cancer the ACC inhibitor drug was able to shrink tumor size by over 60 percent http://ctt.ec/E8Ma7+Compared to untreated animals with cancer the ACC inhibitor drug was able to shrink tumor size by over 60 percent.

Share this!

September 27, 2016 | by Sarah Hand, M.Sc.

To support their rapid growth and proliferation, cancer cells rely on an increased rate of fat synthesis. Researchers at the Salk Institute in La Jolla, California have exploited this requirement by using fat synthesis as a drug target to slow tumor growth, while preserving surrounding healthy tissue.

All cells must synthesize their own fat molecules to support the construction of plasma membranes and other cellular structures, however cancer cells accelerate this process to maintain the rapid growth of tumors. The researchers published their findings in the journal, Nature Medicine.

“Cancer cells rewire their metabolism to support their rapid division,” said Dr. Reuben Shaw, William R. Brody Chair at the Salk Institute, and senior author on the publication. Since Shaw’s team and other researchers have identified a link between fat metabolism and cancer, they sought out to determine whether fat synthesis blocking drugs could be useful anticancer agents.



In partnership with Nimbus Therapeutics, a biotech company based in Boston which focuses on small molecule drug discovery, the team tested a drug candidate in animal models of cancer. The drug – an acetyl-coA carboxylase (ACC) inhibitor called ND-646 – blocks the ACC enzyme which is important in fat synthesis.

Compared to untreated animals with cancer, the ACC inhibitor drug was able to shrink tumor size by over 60 percent. When combined with the DNA damaging drug carboplatin, an effective treatment for non-small cell lung cancer, the power of the experimental inhibitor was boosted.

When combined with ND-646, carboplatin suppressed 87 percent of tumors, compared to only 50 percent when carboplatin was administered on its own. Despite the drug combinations power to significantly slow tumor growth, the researchers say they had no negative impact on healthy cells.

According to Shaw, the study is the first to show that ACC is integral to tumor growth. Along with identifying fat synthesis as a powerful drug target, the team believes they have a “very promising drug” in ND-646, which could be tested in future clinical trials.


Keywords: Cancer, Drug Target, Tumor Growth


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.